Vitiligo Pipeline

DelveInsight’s, “Vitiligo Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

Vitiligo: Understanding

Vitiligo: Overview

Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo appears clinically as milk-white irregularly oval patches of skin, which are small at the beginning but enlarge gradually.  In 2011, an international consensus classified vitiligo into two major forms: nonsegmental vitiligo (NSV) and segmental vitiligo (SV). Vitiligo has an estimated prevalence of 0.5–2% of the population worldwide. There is no difference in prevalence between men and women, but women present more often because of cosmetic concerns.

The main symptom of vitiligo is the appearance of milky-white patches that can be symmetrically distributed on the body, commonly seen on areas like the hands, feet, arms, face, and scalp. These patches can vary in size and shape, ranging from a few millimeters to centimeters, with well-demarcated borders. Vitiligo can also affect hair, turning it white in affected areas, and may involve mucous membranes like the inside of the mouth or nose. Additionally, individuals with vitiligo may experience low self-esteem due to concerns about their appearance, and in some cases, may develop complications like uveitis or inflammation in the ear.

The risk factors for vitiligo are:

Family history and genes- About 30% of people with vitiligo have a family history of this skin disorder. Researchers have found that having a certain genetic profile makes people more susceptible to developing vitiligo.

Environmental triggers- Vitiligo seems to be the result of both a preexisting genetic makeup and something in the environment setting off an autoimmune response that destroys melanocytes.

Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. Multiple mechanisms have been proposed for melanocyte destruction in vitiligo. These include genetic, autoimmune responses, oxidative stress, generation of inflammatory mediators and melanocyte detachment mechanisms. The diagnosis is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). Tests used for diagnosis of vitiligo are microscopic examination, dermoscopy, skin biopsy, and blood test.

 

The optimal treatment of vitiligo will first depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation. First-line treatments consist of topical treatments (corticosteroids and calcineurin inhibitors). Second-line treatments consist of phototherapy (NB-UVB and psoralen and UVA [PUVA]) and systemic steroid treatment. Third-line treatments consist of surgical grafting techniques and fourth-line of depigmenting treatments.

 

"Vitiligo Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve Vitiligo.

 

Vitiligo Emerging Drugs Chapters

This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vitiligo Emerging Drugs

Povorcitinib: Incyte Corporation

Povorcitinib, also known as INCB54707, is a selective JAK1 inhibitor that shows promise as a treatment for vitiligo. It belongs to the family of janus kinase (JAK) inhibitors, which block the JAK signaling pathway involved in the inflammation causing vitiligo. By inhibiting this pathway, povorcitinib indirectly contributes to repigmentation and the disappearance of vitiligo patches. Unlike other JAK inhibitors, povorcitinib's selectivity for JAK1 may reduce certain side effects. Clinical trials have demonstrated the efficacy of povorcitinib in promoting repigmentation in patients with extensive nonsegmental vitiligo, with significant improvements in total body and facial repigmentation observed. The drug has also shown effectiveness in other autoimmune conditions. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Vitiligo

 

VYN 201: Vyne Therapeutics Inc.

VYN201 is an investigational, first-in-class BET (bromodomain and extraterminal) inhibitor designed for topical or localized delivery to treat inflammatory and immune-mediated skin diseases. It works by modulating epigenetic regulators involved in pro-inflammatory gene expression, aiming to reduce inflammation at the source. The product is being explored for dermatological conditions such as vitiligo and other autoimmune skin disorders. VYN201 is currently in early-stage clinical development, with a focus on achieving targeted efficacy while minimizing systemic exposure and side effects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Vitiligo

 

FB 102: Forte Biosciences

FB-102 is an investigational anti-CD122 monoclonal antibody designed to modulate immune pathways involved in autoimmune and inflammatory diseases. It targets the IL-2/IL-15 receptor β-chain (CD122), thereby inhibiting activation and proliferation of T cells and NK cells, key drivers of immune dysregulation. The therapy is being developed for multiple indications including vitiligo, alopecia areata, celiac disease, and graft-versus-host disease (GVHD). FB-102 is currently in early-stage clinical development with both intravenous and subcutaneous routes of administration under evaluation. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Vitiligo

 

Further product details are provided in the report...

 

Vitiligo: Therapeutic Assessment

This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Vitiligo

There are approx. 20+ key companies which are developing the therapies for Vitiligo. The companies which have their Vitiligo drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation

 

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• O

  Introduction Executive Summary Vitiligo: Overview • Introduction • Causes • Pathophysiology • Signs and Symptoms • Diagnosis • Treatment Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Vitiligo– DelveInsight’s Analytical Perspective Late Stage Products (Phase III) • Comparative Analysis Povorcitinib: Incyte Corporation • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis VYN 201: Vyne Therapeutics Inc. • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis FB 102: Forte Biosciences • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Preclinical and Discovery Stage Products • Comparative Analysis Drug profiles in the detailed report….. Unknown Stage Products • Comparative Analysis    Inactive Products • Comparative Analysis Vitiligo Key Companies Vitiligo Key Products Vitiligo- Unmet Needs Vitiligo- Market Drivers and Barriers Vitiligo- Future Perspectives and Conclusion Vitiligo Analyst Views Vitiligo Key Companies Appendix

  al

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Vitiligo: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.

 

Vitiligo Report Insights

Vitiligo Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

 

Vitiligo Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

 

Key Questions Answered In The Vitiligo Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Vitiligo drugs?
• How many Vitiligo drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vitiligo?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vitiligo therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vitiligo and their status?
• What are the key designations that have been granted to the emerging drugs?

 

Key Vitiligo Players

• Incyte Corporation
• Pfizer
• Vyne Therapeutics Inc.
• Elixiron Immunotherapeutics
• Forte Biosciences
• Dren Bio
• Odyssey Therapeutics

 

Key Vitiligo Products in the Market Landscape

• Povorcitinib
• Ritlecitinib
• VYN 201
• EI 001
• FB 102
• DR-01
• OD-00910